Swami Murugappan

Swami Murugappan is responsible for developing and executing the non-clinical and clinical development strategies for the Nutcracker Therapeutics mRNA platform. He leads both non-clinical and clinical functions and is responsible for driving programs from preclinical to IND, execution of clinical studies, and managing regulatory filing activities. Prior to Nutcracker, Swami was the Executive Director and product lead for a CD19 CAR-T (Tecartus™) at Kite Pharma, where he led a successful US and EU filing and subsequent FDA approval of Tecartus™ for relapsed and refractory mantle cell lymphoma. Before Kite, Swami worked at Amgen in early and late phase oncology programs within clinical development and supported global filings and approvals of Vectibix™ and ImLygic™ (first in class Oncolytic virus). Within early phase development, he was the clinical development lead for multiple BiTE® molecules and supported IND enabling activities.

Swami is a board certified Hematologist and Oncologist. He completed his fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center after his Internal Medicine training at Drexel University. He graduated from Temple University with his PhD in Physiology and received his MD degree from Chennai Medical College, India.